ArticleInvestigative ophthalmology & visual science2026
Biallelic Pathogenic Variants in PYGM Impair Retinal Glycogenolysis Causing a Range of Phenotypes.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
Abstract
Purpose: Biallelic pathogenic variants in PYGM (glycogen myophosphorylase) cause glycogen storage disease V (GSDV), a skeletal muscle disorder with reported association with hereditary macular dystrophy (HMD). This study investigated the role of PYGM in HMD and broader retinal disease through clinical and functional analyses. Methods: An autosomal recessive HMD family underwent phenotyping and genome sequencing. Separately, data from 65 patients with GSDV (mean age = 51.7 years) were analyzed for retinal involvement. Immunohistochemistry, RT-qPCR and translating ribosome affinity purification assays assessed retinal expression of glycogen phosphorylase (GP) isoenzymes. Glycogenolysis was studied in retinal pigment epithelial (RPE-1) cells. Retinal sections from PygmR50*/R50* mice were also examined. Results: Genome sequencing identified a homozygous pathogenic stop-gain variant in PYGM (NM_005609.4:c.148C > T; p.[Arg50*]) in the proband and affected sibling, and re-phenotyping revealed features of GSDV. Retinal involvement was identified in 30 of 65 GSDV cases (23 bilateral), with higher prevalence in participants >60 years (approximately 2.6-fold) and men (approximately 2-fold). PYGM expression was localized to Müller glia and photoreceptors. Cell-type-specific GP isoenzyme expression was found in mouse retina and RPE-1 cells. RPE-1 cells demonstrated glycogenolysis. PygmR50*/R50* mice lacked glycogen accumulation but exhibited photoreceptor outer segment thinning consistent with Pygm being the predominant isoform expressed in mouse photoreceptors. Conclusions: GSDV is moderately associated with retinopathy, and may present as non-syndromic HMD, warranting retinal monitoring for patients, and the inclusion of PYGM in retinal dystrophy gene panels. Redundancy in retinal glycogenolysis may account for lower penetrance and higher age-related prevalence in patients. Photoreceptor thinning observed in PygmR50*/R50* mice strengthens the association between HMD and GSDV in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.